| 治疗适应症 | Plaque psoriasis Otulfi is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate (MTX) or PUVA (psoralen and ultraviolet A) (see section 5.1). Paediatric plaque psoriasis Otulfi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older and who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies (see section 5.1). Psoriatic arthritis (PsA) Otulfi, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease- modifying anti-rheumatic drug (DMARD) therapy has been inadequate (see section 5.1) Crohn’s Disease Otulfi is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with lost response to or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies. |
|---|